Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
38.2M
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
30.6M
-
Shares change
-
+526K
-
Total reported value, excl. options
-
$530M
-
Value change
-
+$9.63M
-
Put/Call ratio
-
0.1
-
Number of buys
-
58
-
Number of sells
-
-39
-
Price
-
$17.29
Significant Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) as of Q4 2024
121 filings reported holding TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2024.
Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) has 102 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.6M shares
of 38.2M outstanding shares and own 80.24% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (4.87M shares), 5AM Venture Management, LLC (4.41M shares), MPM ASSET MANAGEMENT LLC (4.38M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.9M shares), JANUS HENDERSON GROUP PLC (2.08M shares), BlackRock, Inc. (1.97M shares), VANGUARD GROUP INC (1.46M shares), FMR LLC (1.4M shares), WELLINGTON MANAGEMENT GROUP LLP (1.03M shares), and StepStone Group LP (761K shares).
This table shows the top 102 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.